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Objectives: The study aimed to assess the suitability of deformable image registration (DIR) software to
generate synthetic CT (sCT) scans for dose verification during radiotherapy to the head and neck. Planning
and synthetic CT dose volume histograms were compared to evaluate dosimetric changes during the
treatment course.
Methods: Eligible patients had locally advanced (stage III, IVa and IVb) oropharyngeal cancer treated with
primary radiotherapy. Weekly CBCT images were acquired post treatment at fractions 1, 6, 11, 16, 21 and
26 over a 30 fraction treatment course. Each CBCT was deformed with the planning CT to generate a sCT
which was used to calculate the dose at that point in the treatment. A repeat planning CT2 was acquired
at fraction 16 and deformed with the fraction 16 CBCT to compare differences between the calculations
mid-treatment.
Results: 20 patients were evaluated generating 138 synthetic CT sets. The single fraction mean dose to
PTV_HR between the synthetic and planning CT did not vary, although dose to 95% of PTV_HR was smal-
ler at week 6 compared to planning (difference 2.0%, 95% CI (0.8 to 3.1), p = 0.0). There was no statistically
significant difference in PRV_brainstem or PRV_spinal cord maximum dose, although greater variation
using the sCT calculations was reported. The mean dose to structures based on the fraction 16 sCT and
CT2 scans were similar.
Conclusions: Synthetic CT provides comparable dose calculations to those of a repeat planning CT; how-
ever the limitations of DIR must be understood before it is applied within the clinical setting.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction neck (H&N) [1–3]. Volumetric arc therapy (VMAT) enables highlyRadiotherapy (RT) is used as a primary treatment or as an
adjunct to surgery in squamous cell cancer (SCC) of the head andconformal RT doses to be delivered to target volumes, whilst
achieving acceptable dose constraints to the organs at risk (OAR)
[3–5]. However, due to the proximity of OAR to target volumes,
H&N radiotherapy planning and treatment delivery remains chal-
lenging [5].
During RT treatment anatomical changes caused by tumour
response, inflammation and weight loss are commonly reported
[1,6]. Discrepancies in patient positioning can affect the delivered
dose, causing increases in the dose to the OAR and reducing dose
to the tumour [1,3,7,8]. Precise immobilisation and image guided
RT (IGRT) is crucial to minimise these effects. IGRT allows set-up
errors to be corrected prior to treatment delivery and ensures the
planned dose is consistently delivered throughout treatment
[8–12].
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adaptive radiotherapy (ART) are not standardised across UK
departments. Repeat computed tomography (CT) or cone-beam
CT (CBCT) are often applied although protocols are dependent on
available clinical resources rather than established best practice
[4,7,11–13]. No guidelines support optimal time points for dose
to be verified during H&N RT, however some studies suggest dosi-
metric changes occur early in the treatment course [8,14,15].
Equally, factors predicting the need for ART (e.g. patient weight
loss, tumour staging etc.) are not well defined [16].
Dose verification in our own centre relies on a repeat planning
CT mid-way through treatment. The treatment dose is recalculated
on the repeat CT and the dose delivered to critical OAR assessed by
the treating oncologist. The process is resource intensive and we
have found through clinical audit that the vast majority of patients
do not require a change to their treatment plan.
Recent studies have suggested that deformable image registra-
tion (DIR) for dose verification during radiotherapy may be useful
[1,4]. An example of this is using the CBCTs obtained during the
treatment course to deform and register the planning CT (pCT) to
the CBCT anatomy. This generates a synthetic CT (sCT) set with
the Hounsfield units (HU) of the planning CT. This allows monitor-
ing of the patient’s treatment plan at different points during the
course introducing greater potential for the implementation of
ART.
The aim of this study was to assess the suitability of DIR soft-
ware to generate synthetic CT scans for dose verification during
radiotherapy to the H&N. Differences in dosimetry data obtained
from the planning and synthetic CT dose volume histograms
(DVHs) were evaluated during the treatment course.Methods
Patient selection
Eligible patients had locally advanced (stage III, IVa and IVb,
UICC/AJCC TNM staging system 7th edition) oropharyngeal squa-
mous cell cancer (OPSCC) and received primary RT or chemoradio-
therapy (CRT).
Ethical consideration
Patients were treated and consented as standard of care; there-
fore no ethical approval was required. This retrospective service
evaluation was approved by the Beatson West of Scotland Cancer
Centre’s management group and NHS Greater Glasgow and Clyde’s
Research and Development department.
Immobilisation & planning CTs
Patients were positioned supine, immobilised with a custom
made 5-point thermoplastic head and shoulder mask (Klarity Med-
ical Products, Newark, Ohio), individual foam headrest and knee
support. Planning CTs were obtained using a Phillips Brilliance
Big Bore scanner (Philips Medical Systems B.V, The Netherlands);
slice thickness 2 mm. Scan extent was from vertex to below carina.
Planning CTs were acquired at baseline (pCT1) and at fraction 16 of
radiotherapy (pCT2). Intravenous contrast was given to patients for
the baseline CT but not at fraction 16.
Target delineation & treatment
Gross tumour volumes (GTV) consisting of the primary tumour
and known involved lymph nodes were delineated by the clinical
oncologist (CO) [17]. GTVs were grown by 1–2 cm to create highrisk clinical target volumes (CTV_HR). A margin of 3–5 mm around
the CTVs was applied to generate the high risk planning target vol-
umes (PTV_HR) [18,19]. Low risk nodal areas were outlined to gen-
erate low risk clinical and planning target volumes respectively
(CTV_LR and PTV_LR). Planning organ at risk volumes (PRV) were
generated by applying a 3–5 mm isotropic margin around critical
OAR. PTVs were cropped from body surface by 5 mm to account
for calculation uncertainties in the planning algorithm.
The prescribed dose was 6500 cGy to PTV_HR and 5400 cGy to
PTV_LR in 30 fractions. VMAT plans were created within the Eclip-
seTM treatment planning system (TPS) (Varian Medical System, Palo
Alto, CA) and optimised using the inverse planning Analytical Ani-
sotropic Algorithm (AAA Version 13.6.23). The department proto-
col for the head and neck VMAT dose constraints was established
through the outcomes of the PARSPORT trial [20]. Dose constraints
applied were mean dose (Dmean) < 2400 cGy for parotid glands
(PG), maximum dose (Dmax)  4800 cGy for PRV_spinal cord,
Dmax < 5400 cGy for PRV_brainstem and dose to 95% of the
PTV_HR (D95%)  95% of the prescribed dose. Target volume dose
coverage and OAR sparing was visually assessed and quantified
using DVHs.
Treatment was delivered using 6MV VMAT, 2 full arcs, 600MU/
min, on a TrueBeam linear accelerator. Cisplatin 100 mg/m2, day
1 and 22 was given concurrently with radiotherapy in eligible
patients.
Image verification process
Orthogonal KV-images were registered with a digitally recon-
structed radiograph (DRR) created from pCT1 and online shifts
applied daily prior to treatment delivery. A post-treatment CBCT
was acquired at fractions 1, 6, 11, 16, 21 and 26. Due to the limited
field of view (FoV) on CBCT compared to pCT1, priority was given
to inclusion of the brainstem and where possible also PTV_HR in
the overlap region, meaning not all structures were included in
their entirety in the CBCTs. Each CBCT was reviewed offline by
the clinician who evaluated soft tissue changes, volumetric data
and the dose distribution.
Contouring and image registration
An offline rigid image registration between each CBCT and pCT1
was performed in the image registration workspace of EclipseTM.
The region of interest (ROI) was manually selected by the thera-
peutic radiographer (RTT) as mid brainstem to below PTV_HR in
the craniocaudal direction, behind spinal vertebrae posteriorly
and inclusive of the mandible anteriorly. This ROI was applied to
all registrations within the study. The images were rigidly regis-
tered using the auto-registration tool to align the bony anatomy.
The structure set from pCT1 was then duplicated to each CBCT
scan. A visual check of the structures on the CBCT was undertaken
to confirm the match. In the contour workspace, the parotid glands
were manually amended on each CBCT, by the investigating RTT
and checked by the CO. The original structures were applied to
all registrations throughout the study, with the exception of the
parotid glands. There was insufficient clarity on the CBCT and
sCT to make adjustment to other structures.
Deformable synthetic image creation
The DIR software used during the study was Varian VelocityTM.
The starting point for the DIR process was the rigid online CBCT-
pCT match [21]. A b-spline deformation algorithm (3-pass deform-
able registration for finer detail) was used with a noise filter
applied to the CBCT to reduce noise, enhance the image contrast
and to improve the DIR process.
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and then reshaped, to create a synthetic CT through DIR. The sCT
is a new image set where the volume boundaries are the same as
the CBCT within the overlap region. Outside the overlap area the
primary voxels were copied without deformation. The deformed
reshaped volume (sCT) has the Hounsfield units (HU) of the pri-
mary CT1 and the anatomy of the CBCT within the overlap region
of both the images involved in the DIR. To validate the generated
sCT a rigid registration between the sCT and CBCT was undertaken
and visually assessed using the spy glass tool.DIR quality assurance (QA) process
The DIR depends on the image similarity and acquisition qual-
ity. For evaluating our deformable fusions and the resulting sCTs,
the VelocityTM QA toolkit was used as follows:
- Deformable vector field and grid analysis: Velocity allows quick
display of the direction vectors and/or displacement grid to
review the manner and method voxels deformed over the vol-
ume. This allows evaluation of cases where voxels may have
not displaced in congruence with their regional neighbours,
such as voxel jumping, unnatural folding, or extreme volume
changes.
- Spy Glass Tool – Allows visual image assessment to verify the
alignment of the tissue overlay, to detect unusual characteris-
tics or mismatches, such as holes, gaps, swirling, folding and
extreme shrinking or stretching.
The DIR was visually validated by VelocityTM competent physi-
cists and a RTT. The sCT images were assessed by visually analysing
their likeness to the CBCT, evaluating the volumes appearance as
described above (Fig. 1).Fig. 1. Deformable image reImage registration – CBCT with sCT
After DIR, each sCT was imported and rigidly registered with the
CBCT within the TPS. The amended CBCT structure set was then
copied to the corresponding sCT. The structures were visually
assessed on the sCT for any discrepancies which may have
occurred during the deformation process; however no further
amendments were made to the structure set.
Plan re-calculation and dose comparison
Fig. 2 outlines the points during treatment when sCT images
were created. Verification plans were created for each sCT data
set and the dose was re-calculated by applying the pre-set monitor
unit values of the original pCT1 plan. The planned cumulative dose
during treatment based on pCT1 was compared to the observed
cumulative dose based on the weekly sCT plans.
Comparison of the 95% dose distribution to PTV_HR on both the
sCT and pCT was visually assessed for similarity, using the dose
colour wash. The dose coverage, the dose conformance with the
volume, areas outside the volume which were receiving 95% of
dose and the position of any hotspots greater than 105% were
assessed. The dose distribution on the sCT was acceptable if it
showed a likeness to the pCT1 plan used for treatment and the
department dose constraints were met, during DVH comparison
(Fig. 3).
Mid-point dose verification
At fraction 16 a rigid registration between pCT1 and planning
CT2 (pCT2) was performed. The structure set from pCT1 was copied
to pCT2, after the bony anatomy was aligned within the ROI.
Within the external beam planning workspace the dose wasgistration QA process.
TM
Fig. 2. Study flow.
Fig. 3. Example of 95% dose distribution between the synthetic CT and planning CT1 at fraction 16.
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of the original pCT1 plan, allowing a visual evaluation of the treat-
ment dose distribution on the repeat pCT2. The proximity of the
dose to spinal cord and brainstem was given priority.
DIR between the fraction 16 CBCT and pCT2 was undertaken to
create #16sCT2, as well as #16sCT1 (fraction 16 CBCT and pCT1). A
rigid image registration between each fraction 16 CBCT and pCT2
was performed, within the selected ROI as previously described.
The structure set from the fraction 16 CBCT with the parotid glands
re-delineated was applied to pCT2. The rigid registration was
imported to VelocityTM for DIR to generate #16sCT2. A further rigid
registration in theTPS toalign the fraction16CBCTand#16sCT2was
performed and the structure set copied from CBCT to the #16sCT2.
This allowed a QA evaluation of the #16sCT2 re-calculated dose,
compared with the pCT2 dose calculation both undertaken at the
same point in treatment. Identical image registration and dose
assessment procedures were used as previously described.Data collection
Planning and imaging information was collected from the
department’s TPS.
Patient information was stored and analysed anonymously.Data analysis
Paired t-testswere used to analyse statistical differences inmean
dose and volumes for plans based on the original pCT1 and sCTs at
fractions 1, 6, 11, 16, 21 and 26. Repeated measures ANOVA wereFig. 4. Tissue overestima
Table 1
Tumour staging of patients.
T Stage: % n
0 5 1
1 25 5
2 31 6
3 25 5
4 14 3
N Stage: % n
1 65 13
2 30 6
3 5 1used to test for differences between weekly sCTs. The ‘planned’
cumulative dose based on the pCT1 was compared to the ‘observed’
cumulative dose based on the sum of the dose derived from the sCT
plans. Bland-Altman limits of agreementwere calculated at fraction
16 between #16sCT1 and CT2. All statistical tests were 2 sided and a
significance level of 0.05 was applied.
Data analysis was carried out using Stata Statistical Software:
Release 14 (TX: StataCorp LP).
Results
Patient demographics
20 consecutive patients were identified between October 2017
and January 2018. Sixty-five percent were male and 35% female,
median age was 59 years (range 47–72). Sub-sites treated included
tonsil (11), base of tongue (4), oropharynx not otherwise specified
(4) and pharyngeal wall (1). 70% of patients had human papilloma
virus (HPV) related SCCs and 80% received chemotherapy. TNM
classification is shown in Table 1.
Image evaluation & anatomical changes
138 synthetic CT scans were evaluated, an example is shown in
Fig. 3. The generated sCT image sets were found to be visually
acceptable unless contour differences between the CBCT and
pCT1 were greater than 1 cm (Fig. 4).
1 patient at fraction 16 had a gap on CBCT > 1 cm, which was
not demonstrated on the sCT. This increased to 4, then 5 patients
at fractions 21 and 26 respectively. Therefore 10 sCT scans gener-
ated during the DIR had the gap from the CBCT underestimated.
The gap between the immobilisation masks and the patient’s
body contour increased throughout treatment. By fraction 26 the
CBCT mean gap was 0.92 cm (SD 0.45 cm) and 0.28 cm (SD
0.32 cm) based on the sCT (Table 2).
Both ipsilateral and contralateral PGs decreased in volume dur-
ing treatment as shown in Table 3.
Comparison of weekly sCT single fraction dose
The mean single fraction dose to the ipsilateral parotids
increased from 137.2 cGy at planning to 146.4 cGy at week 6 (dif-tion on synthetic CT.
Table 2
Variation in gap at Isocentre between CBCT and synthetic CT at fractions 16, 21 & 26.
Maximum Gap at Isocentre from skin surface to BDS
#16 (cm) #21 (cm) #26 (cm)
CBCT sCT CBCT sCT CBCT sCT
Mean 0.53 0.25 0.84 0.35 0.92 0.28
SD 0.40 0.29 0.33 0.35 0.45 0.32
Median 0.65 0.20 0.80 0.30 0.75 0.20
Range 0–1.2 0–0.9 0–1.5 0–1 0–2 0–1
*Beam Direction Shell (BDS).
Table 3
Mean volume and dosimetry values at each week for one fraction.
Mean (SD) ANOVA* p
value
Planning CT Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Volume (CC) Ipsilateral
Parotid gland
28.8 (11.5) 29.0 (11.5) 28.3 (11.1) 27.4 (11.2) 26.1 (11.2) 24.1 (10.2) 22.7 (9.4) <0.0001
Contralateral
Parotid gland
28.6 (10.6) 28.5 (11.0) 27.9 (9.8) 26.9 (9.8) 26.1 (9.9) 24.1 (9.0) 23.5 (9.4) <0.0001
Mean Dose
(cGy)
PTV_HR 218.2 (1.3) 218.1 (1.3) 217.7 (2.4) 217.8 (1.8) 218.1 (1.8) 218.2 (1.9) 217.9 (1.8) 0.42
Ipsilateral
parotid gland
137.2 (25.2) 137.6 (28.7) 136.7 (29.8) 136.6 (30.0) 136.8 (27.8) 142.2 (29.0) 146.4 (29.4) <0.0001
Contralateral
parotid gland
86.9 (31.2) 89.4 (31.3) 88.1 (30.3) 89.0 (31.0) 89.7 (31.1) 92.0 (31.6) 93.3 (33.2) 0.0162
D95% PTV_HR 96.6 (1.8) 95.5 (3.2) 95.2 (2.9) 94.8 (3.4) 95.1 (2.6) 94.4 (3.6) 94.6 (3.2) 0.34
Maximum
dose (cGy)
PRV_Brainstem 146.2 (12.9) 145.4 (20.9) 146.2 (20.3) 147.1 (21.0) 146.9 (21.3) 146.4 (19.2) 150.8 (20.2) 0.39
PRV_Spinal
cord
139.5 (6.5) 140.7 (15.2) 141.0 (14.7) 143.4 (17.6) 142.5 (15.0) 142.8 (13.9) 142.3 (15.1) 0.87
*ANOVA test of difference between mean values across weeks.
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tralateral parotids rose from 86.9 cGy to 93.3 cGy (difference
6.4 cGy 95%CI (2.5–10.4)). The mean dose to PTV_HR did not vary
(p = 0.42) during treatment, but D95% was smaller at week 6
(94.6%) compared to what had been planned (96.6%) (difference
2.0%, 95% CI (0.8–3.1), p = 0.0). Overall, there was no statistically
significant difference in PRV_brainstem or PRV_spinal cord Dmax,
however Dmax displayed greater variation than shown at
planning.
Cumulative dose comparison
Table 4 shows the difference in ‘observed’ and ‘planned’ cumu-
lative dose to organs. The difference in the observed and planned
cumulative mean dose was 10 cGy (range 90 to 90 cGy) for
PTV_HR, and 50 cGy (range 340 to 440 cGy) and 90 cGy (range
550 to 470 cGy) for the ipsilateral and contralateral parotids
respectively. The mean difference in cumulative maximum dose
to PRV_spinal cord and PRV_brainstem was 80 cGy (range 310
to 950 cGy) and 20 cGy (range 720 to 630 cGy) respectively.
Based on the sCTs one patient exceeded the PRV_spinal cord
constraint Dmax < 4800 cGy - the dose was 5180 cGy. All patientsTable 4
Observed and planned cumulative dose based on planning CT and weekly synthetic CTs.
Cumulative dose (cGy) or (%)
Planned Range Observed
Mean dose PTV_HR 6550 6480 to 6610 6540
Ipsilateral
parotid gland
4120 3000 to 5940 4170
Contralateral parotid gland 2610 440 to 3970 2700
Max dose PRV_Brainstem 4390 3350 to 4920 4410
PRV_Spinal Cord 4180 3590 to 4460 4260
D95% PTV_HR 96.6 90.2 to 98.4 94.8were within the Dmax constraint for PRV_brainstem. The differ-
ence in the planned and observed relative dose received by 95%
of the PTV_HR varied from 6.0% to 0.4% with a mean difference
of 1.8% (95%CI 2.6 to 1.0%). Based on the pCT 19 of the 20
plans achieved the constraint D95%95 to PTV_HR throughout
treatment but based on sCTs this was only 13 (65%).
Plan comparisons fraction 16
Table 5 shows the mean dose to the original structures based on
the fraction 16 sCTs and pCT2 at week 4 are similar, between both
verification modalities.
All 20 patients’ met the dose constraints for Dmax to
PRV_brainstem based on the #16sCT1 plans, however the
PRV_spinal cord constraint failed in 3 patients. In contrast all
patients passed the PRV_spinal cord constraint based on CT2.
Fig. 5 shows the Bland-Altman limits of agreement of dosimetry
measures comparing #16sCT1 and CT2. Agreement between mean
doses to PTV_HRwaswithin approximately +/3cGY. Formeandose
to the ipsilateral and contralateral PG’s the values laywithin approx-
imately +/ 20 cGy. For maximum dose to PRV_brainstem and
PRV_spinal cord the limits of agreement suggest that #16sCT1Difference (cGy) or (%)
Range mean difference range 95% CI for mean difference
6420 to 6610 10 90 to 90 20 to 10
2780 to 5990 50 340 to 440 50 to 160
430 to 3940 90 550 to 470 20 to 210
3120 to 5350 20 720 to 630 130 to 170
3330 to 5180 80 310 to 950 70 to 230
86.6 to 97.9 1.8 6.0 to 0.4 2.6 to 1.0
Table 5
Comparison of volumes and dosimetry based on a synthetic CT created from CT1 with CT2 at fraction 16.
Planning CT1 #16 synthetic CT1 CT2 at fraction 16 #16 synthetic CT2
Mean SD Mean SD Mean SD Mean SD
Volume (cc) Ipsilateral
Parotid Gland
28.8 (11.5) 26.1 (11.2) 26.1 (11.3) 26.3 (11.3)
Contralateral
Parotid Gland
28.6 (10.6) 26.1 (9.9) 25.9 (10.0) 26.2 (10.0)
Mean dose (cGy) PTV_HR 218.2 (1.3) 218.1 (1.8) 218.4 (2.2) 218.1 (2.3)
Ipsilateral 137.2 (25.2) 136.8 (27.8) 137.2 (27.6) 136.7 (27.0)
contralateral 86.9 (31.2) 89.7 (31.1) 87.0 (29.9) 86.8 (29.2)
Maximum dose (cGy) PRV_Brainstem 146.2 (12.9) 146.9 (21.3) 143.0 (17.0) 145.5 (23.7)
PRV_Spinal Cord 139.5 (6.5) 142.5 (15.0) 138.3 (9.3) 140.9 (15.5)
D95% PTV_HR 96.6 (1.8) 95.1 (2.6) 94.9 (4.5) 93.6 (6.9)
n (%) n (%) n (%) n (%)
D95%<95% PTV_HR 1 (5) 6 (30) 6 (30) 7 (35)
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Fig. 5. Limits of agreement between #16sCT1 and CT2 mean dose differences.
L.K Hay et al. / Technical Innovations & Patient Support in Radiation Oncology 14 (2020) 21–29 27underestimates the maximum dose when the dose is low and over
estimates it when the dose is high, but overall the values were
approximately within +/30 cGy. PTV_HR is approximately within
+/5% but there is also a suggestion that PTV_HR D95% is over esti-
matedwhen thedose is lower andunder estimatedwhen it is higher.Discussion
This study explored the use of CBCT and synthetic CT to calcu-
late dose and guide ART in H&N patients. The differences we found
in the dosimetry data between the planning CT and synthetic CTsgenerated during treatment were small. Previous studies report
uncertainty in the use of DIR as a clinical tool for verifying cumu-
lative doses due to differences found between DIR algorithms
[8,22–24].Synthetic CT and anatomical change
The majority of the deformations generated sCT images without
gross distortions when compared to the original CBCT, although
distortion on some of the sCT images was observed. Anatomical
changes can be well visualised on CBCT to evaluate changes in tar-
28 L.K Hay et al. / Technical Innovations & Patient Support in Radiation Oncology 14 (2020) 21–29get volume, patient contour variation (caused by weight loss,
tumour changes etc.) and shifts in delineated planning volumes
[8,16,25,28]. One patient within this study had bolus in situ during
their CBCT scans but not on their pCT. This created extra tissue on
the generated sCT. The bolus was not included in the delineated
body outline; therefore it had no effect on the dose calculations
within the TPS. The patient’s, CBCT displayed regression of a nodal
GTV at week 6 measuring 1.5 cm. This did not trigger replanning,
as the residual disease volume was still well contained within
the PTV and the dose coverage remained adequate. This study visu-
ally assessed delineated structures and patient contour changes.
Other anatomical variations will be assessed in future work. A
recent study evaluated contour changes > 1.5 cm between gener-
ated sCTs and CBCT to guide ART during treatment [26]. Our study
identified that when patient’s contour changes were > 1 cm the DIR
software failed to correctly recognise the soft tissue during the
deformation, although this had a minimal effect on the calculated
dose distributions. Previous studies confirm this finding, reporting
that image quality with DIR deteriorates during the treatment
course, as the algorithm struggles to account for large changes in
volumes [22–27]. In such cases where deformation is still unac-
ceptable after corrections applied, repeat CT would be necessary
to make accurate clinical decisions and volume amendments.
Dose comparison between sCT and pCT
Defining spinal cord and brainstem tissue on CBCT is challeng-
ing due to poor image contrast [27]. Consequently we did not rev-
olume these structures. A limitation of this study is that the
structure set was not deformed and DVH statistics are based on
the original structures, except the parotid glands. To ensure the
other structures were still valid, a visual check of the structures
applied to the sCT was carried out. Future work will investigate
structure deformation as it is recognised this may provide better
representation of the dose to the structures based on that fraction’s
anatomical positioning. Acquiring extended CBCT scans, or priori-
tising the acquisition of structures contained within the FOV, could
allow these volumes to be assessed in more detail [4,24]. This is an
area of work being investigated currently.
We did identify a reduction in parotid gland volumes during
treatment based on the CBCT delineations and the synthetic CT
dose calculations showed an increasing mean dose to the parotids
at each fraction they were generated. Dose delivered to the gross
disease is given priority therefore any dose increase to the ipsilat-
eral parotid gland would not trigger re-planning due to the close
proximity of the PTV_HR. Adaptive planning to spare the contralat-
eral PG is not standard practice in our Centre, although other stud-
ies have reported this [28].
For PTV_HR no difference between the planned and observed
mean dose was detected, although D95% was lower at week 6 by
2% on the sCT plans. This observed reduction in the dose to 95%
of PTV_HR may be a result of the short CBCT FOV, as the entire
PTV_HR structure was not consistently captured within the scan
extent. Further assessment of the structures within the FOV is nec-
essary to determine this. We also detected a cumulative decrease
of 1.8% in the 95% dose delivered to PTV_HR between the planned
and observed doses. The reduction in dose to the target volume is
consistent with findings in other studies [29,30].
Verification at mid-treatment sCT vs. pCT2
At fraction 16 the differences in the synthetic CT plans created
by deforming the CBCT with both CT1 and CT2 were compared. We
found no statistically significant differences between the plan cal-
culations based on #16sCT1 and pCT2. This suggests that dose con-
straint evaluation on the #16sCT1 might be a useful planningguide. Dose constraints were achieved for all patients at fraction
16 using the repeat pCT2 verification plan; however 3 patients
failed the PRV_spinal cord constraint on the #16sCT1 plan. Evalu-
ation of the difference in the mean maximum doses between
#16sCT1 and pCT2 using Bland Altman limits of agreement sug-
gested potential proportional biases in the sCT calculated doses
to PRV_spinal cord and PRV_brainstem. The Bland Altman plots
suggested that #16sCT1 underestimated Dmax when the dose is
low and overestimated Dmax when the dose is high. The net effect
is that calculations based on sCT would potentially trigger more
re-plans than necessary, which is in agreement with previous
study findings [14]. This cautious process would not compromise
patient safety. The mean dose to PTV_HR between CT1 and CT2
remained the same at fraction 16, although D95% declined. This
requires further assessment of the dose coverage to PTV_HR during
treatment to ensure the delivered dose does not become unaccept-
able, potentially increasing patient’s risk of recurrence. Further
investigation of this finding is necessary as dose to PTV_HR is not
formally reassessed at fraction 16 within our current protocol.
DVH statistics were also comparable at fraction 16, though aware-
ness of the limitations of DIR is essential when assessing volumes.
Anatomical changes are reported to occur early within the first
4 weeks of RT, justifying the need for repeated imaging and replan-
ning during this period [8,14,15,25,28]. A verification process such
as described herewould increase availability on CT for all treatment
sites within this busy department, whilst potentially reducing
patient anxiety as many expect ‘results’ from the repeat planning
CT. The safe omission of repeat CT during H&N RT has been previ-
ously justified [4,31]. Many institutions already acknowledge the
benefit of rigid registrations using CBCT for on-treatment image
guidance; and identifying anatomical changes. However, the wide-
spread implementation of CBCT used for DIR as a sole dose verifica-
tion modality in the clinical setting is constrained by its limitations
and complexity. In particular, DIR remains problematic in cases
where large changes in patient contour are identified [1,4,13].Conclusions
Synthetic CT verification provides similar dose calculations to
those of a repeat planning CT. There are limitations and uncertain-
ties in the use of DIR and its algorithms which must be fully under-
stood before such a process is applied routinely in the clinical
setting. When this is achieved, sCT could stratify patients requiring
planning interventions, at more targeted time points during the
treatment course. If replanning was considered necessary on the
basis of sCT dosimetry, patients could then undergo a repeat plan-
ning CT for confirmation, with adaptive planning being performed
on the pCT. This would eliminate routine repeat pCTs for dose veri-
fication, thereby leading to a reduction in the number of pCTs
required, with the necessary scans obtained at themost appropriate
time point.Advances in knowledge
This study presents an evaluation of head and neck dose verifi-
cation during radiotherapy with the objective of reducing routine
repeat CT scans, demonstrating the potential of CBCT and synthetic
CT as a feasible approach for verification, whilst describing the lim-
itations of this methodology.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
L.K Hay et al. / Technical Innovations & Patient Support in Radiation Oncology 14 (2020) 21–29 29Acknowledgement
Thank you to the Beatson Cancer Charity.References
[1] Elstrøm UV, Wysocka BA, Muren LP, Petersen JBB, Grau C. Daily kV cone-beam
CT and deformable image registration as a method for studying dosimetric
consequences of anatomic changes in adaptive IMRT of head and neck cancer.
Acta Oncol 2010;49(7):1101–8. https://doi.org/10.3109/
0284186X.2010.500304.
[2] Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF,
et al. Prevalence and peak incidence of acute and late normal tissue morbidity
in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head
and neck cancer. Radiother Oncol 2012;103(1):69–75. https://doi.org/10.1016/
j.radonc.2012.01.002.
[3] Hermans BC, Persoon LC, Podesta M, Hoebers FJ, Verhaegen F, Troost EG.
Weekly kilovoltage cone-beam computed tomography for detection of dose
discrepancies during (chemo) radiotherapy for head and neck cancer. Acta
Oncol 2015;54(9):1483–9. https://doi.org/10.3109/0284186X.2015.1061210.
[4] Ayyalusamy A, Vellaiyan S, Shanmugam S, Ilamurugu A, Gandhi A, Shanmugam
T, et al. Feasibility of offline head & neck adaptive radiotherapy using deformed
planning CT electron density mapping on weekly cone beam computed
tomography. Br J Radiol 2017;90(1069):20160420. https://doi.org/10.1259/
bjr.20160420.
[5] Hansen CR, Bertelsen A, Hazell I, Zukauskaite R, Gyldenkerne N, Johansen J,
et al. Automatic treatment planning improves the clinical quality of head and
neck cancer treatment plans. Clin Translational Radiat Oncol 2016
December;2016(1):2–8. https://doi.org/10.1016/j.ctro.2016.08.001.
[6] Rigaud B, Simon A, Castelli J, Gobeli M, Ospina Arango JD, Cazoulat G, et al. PO-
0935: Evaluation of deformable image registration methods for dose
monitoring in head and neck adaptive radiotherapy. Radiother Oncol 2015
April;2015(115):S488–9. https://doi.org/10.1155/2015/726268.
[7] Müller BS, Duma MN, Kampfer S, Nill S, Oelfke U, Geinitz H, et al. Impact of
interfractional changes in head and neck cancer patients on the delivered dose
in intensity modulated radiotherapy with protons and photons. Physica Med
2015;31(3):266–72. https://doi.org/10.1016/j.ejmp.2015.02.007.
[8] van Kranen S, Hamming-Vrieze O, Wolf A, Damen E, van Herk M, Sonke J. Head
and neck margin reduction with adaptive radiation therapy: robustness of
treatment plans against anatomy changes. Int J Radiat Oncol Biol Phys 2016;96
(3):653–60. https://doi.org/10.1016/j.ijrobp.2016.07.011. 1 November 2016.
[9] Houweling AC, van der Meer S, van der Wal E, Terhaard CHJ, Raaijmakers CPJ.
Improved immobilization using an individual head support in head and neck
cancer patients. Radiotherapy Oncology 2010 July 2010;96(1):100–103.
https://doi.org/10.1016/j.radonc.2010.04.014.
[10] Hvid CA, Elstrøm UV, Jensen K, Alber M, Grau C. Accuracy of software-assisted
contour propagation from planning CT to cone beam CT in head and neck
radiotherapy. Acta Oncol 2016;55(11):1324–30. https://doi.org/10.1080/
0284186X.2016.1185149.
[11] Bell K, Licht N, Rübe C, Dzierma Y. Image guidance and positioning accuracy in
clinical practice: influence of positioning errors and imaging dose on the real
dose distribution for head and neck cancer treatment. Radiat Oncol
2018;13:190. https://doi.org/10.1186/s13014-018-1141-8.
[12] Kumarasiri K, Siddiqui F, Liu C, Yechieli R, Shah M, Pradhan D, et al. Deformable
image registration based automatic CT-to-CT contour propagation for head
and neck adaptive radiotherapy in the routine clinical setting. Int J Med Phys
2014;41(12). https://doi.org/10.1118/1.4901409. pp. 121712–1- 121712–10.
[13] Leech M, Coffey M, Mast M, Moura F, Osztavics A, Pasini D, et al. Guidelines for
positioning, immobilisation and position verification of head and neck patients
for RTTs. ESTRO 2016. https://doi.org/10.1016/j.tipsro.2016.12.001.
[14] Bhandari V, Patel P, Gurjar OP, Gupta KL. Impact of repeat computerized
tomography replans in the radiation therapy of head and neck cancers. J Med
Phys 2014 Jul;39(3):164–8. http://www.jmp.org.in/text.asp?2014/39/3/164/
139005.
[15] Brown E, Owen R, Harden F, Mengersen K, Oestreich K, Houghton W, et al.
Predicting the need for adaptive radiotherapy in head and neck cancer.Radiotherapy Oncol 2015 July 2015; 116(1):57–63. http://dx.doi.org/10.1016/
j.radonc.2015.06.02.
[16] Noble DJ, Yeap P, Seah SYK, Harrison K, Shelley LEA, Romanchikova M, et al.
Anatomical change during radiotherapy for head and neck cancer, and its
effect on delivered dose to the spinal cord. Radiother Oncol 2019 January;2019
(130):32–8. https://doi.org/10.1016/j.radonc.2018.07.009.
[17] Chuter R, Prestwich R, Bird D, Scarsbrook A, Sykes J, Wilson D, et al. The use of
deformable image registration to integrate diagnostic MRI into the
radiotherapy planning pathway for head and neck cancer. Radiotherapy
Oncol 2017 February 2017;122(2):229-235. https://doi.org/10.1016/j.
radonc.2016.07.016.
[18] Grégoire V, Grau C, Lapeyre M, Maingon P. Target volume selection and
delineation (T and N) for primary radiation treatment of oral cavity,
oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma. Oral
Oncol 2018 December;2018(87):131–7. https://doi.org/10.1016/j.
oraloncology.2018.10.034.
[19] Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al.
Delineation of the neck node levels for head and neck tumors: A 2013 update.
DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus
guidelines. Radiotherapy Oncol 2014;110:172–81. https://doi.org/10.1016/j.
radonc.2013.10.010.
[20] Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al.
Parotid-sparing intensity modulated versus conventional radiotherapy in head
and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled
trial. Lancet Oncol 2011;12(2):127–36. https://doi.org/10.1016/S1470-2045
(10)70290-4.
[21] Varian medical systems, Velocity user manual. Velocity 3.2.0. Published USA;
2016. Available from: https://www.varian.com/sites/default/files/
resource_attachments/Velocity3.2.0DicomConformanceStatement.pdf.
[22] Veiga C, Lourenço AM, Mouinuddin S, van Herk M, Modat M, Ourselin S, et al.
Toward adaptive radiotherapy for head and neck patients: Uncertainties in
dose warping due to the choice of deformable registration algorithm. Med
Phys 2015;42(2):760–9. https://doi.org/10.1118/1.4905050.
[23] Eiland RB, Maare C, Sjostrom D, Samsoe E, Behrens CF. Dosimetric and
geometric evaluation of the use of deformable image registration in adaptive
intensity-modulated radiotherapy for head-and-neck cancer. J Radiat Res
2014;55(5):1002–8. https://doi.org/10.1016/S0167-8140(12)71226-4.
[24] Mencarelli A, van Kranen SR, Hamming-Vrieze O, van Beek S, Nico Rasch CR,
van Herk M, et al. Deformable image registration for adaptive radiation
therapy of head and neck cancer: accuracy and precision in the presence of
tumor changes. Int J Radiat Oncol Biol Phys 2014;90(3):680–7. https://doi.org/
10.1016/j.ijrobp.2014.06.045.
[25] van Beek S, Jonker M, Hamming-Vrieze O, Al-Mamgani A, Navran A, Remeijer
P, et al. Protocolised way to cope with anatomical changes in head & neck
cancer during the course of radiotherapy. Tech Innovations Patient Support
Radiat Oncol 2019;12:34–40. https://doi.org/10.1016/j.tipsro.2019.11.001.
[26] Weppler S, Quon H, Banerjee R, Schinkel C, Smith W. Framework for the
quantitative assessment of adaptive radiation therapy protocols. J Appl Clin
Med Phys 2018;19(6):26–34. https://doi.org/10.1002/acm2.12437.
[27] Roussakis YG, Dehghani H, Green S, Webster GJ. Validation of a dose warping
algorithm using clinically realistic scenarios. Br J Radiol 2015 May;88:1049.
https://doi.org/10.1259/bjr.20140691.
[28] Brouwer CL, Steenbakkers RJHM, Langendijk JA, Sijtsema NM. Identifying
patients who may benefit from adaptive radiotherapy: Does the literature on
anatomic and dosimetric changes in head and neck organs at risk during
radiotherapy provide information to help? Radiother Oncol 2015;115
(3):285–94. https://doi.org/10.1016/j.radonc.2015.05.018. June 2015.
[29] Surucu M, Shah KK, Roeske JC, Choi M, Small W, Emami B. Adaptive
radiotherapy for head and neck cancer: implications for clinical and
dosimetry outcomes. Technol Cancer Res Treat 2017;16(2):218–23. https://
doi.org/10.1177/1533034616662165.
[30] Grégoire V, Jeraj R, Lee JA, O’Sullivan B. Radiotherapy for head and neck
tumours in 2012 and beyond: conformal, tailored, and adaptive? Lancet Oncol
2012;13(7):e292–300. https://doi.org/10.1016/S1470-2045(12)70237-1. July
2012.
[31] Hvid CA, Elstrøm UV, Jensen K, Grau C. Cone-beam computed tomography
(CBCT) for adaptive image guided head and neck radiation therapy. Acta Oncol
2018;57(4):552–6. https://doi.org/10.1080/0284186X.2017.1398414.
